Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abrocitinib - Pfizer

Drug Profile

Abrocitinib - Pfizer

Alternative Names: CIBINQO; Cibinqo; JAK 1 inhibitor - Pfizer; PF 04965842; PF-4965842

Latest Information Update: 05 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer National Institute of Diabetes and Digestive and Kidney Diseases; Pfizer
  • Class Amines; Anti-inflammatories; Antihyperglycaemics; Antipsoriatics; Cyclobutanes; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • Phase II Prurigo nodularis; Pruritus; Sarcoidosis; Type 1 diabetes mellitus
  • Discontinued Lupus vulgaris; Plaque psoriasis

Most Recent Events

  • 19 Jun 2024 An Expanded Access Protocol from Pfizer in Atopic dermatitis (In adolescents, In adults) no longer available (PO) (NCT04564755)
  • 16 Apr 2024 Registered for Atopic dermatitis (Treatment-experienced, In adults) in Australia (PO)
  • 27 Mar 2024 Pharmacokinetics data from phase-I trial in healthy volunteers presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024))
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top